Studies done after the introduction of Herceptin, and other HER2-targeted therapies, have found that HER2-positive breast cancers continue to have a relatively high incidence of brain metastases.

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

In 1998, Herceptin (trastuzumab), the first medication to directly target HER2, was approved by the FDA. Oncologists usually start with this drug before trying other treatments.

Key Takeaways Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% ...

In patients with HER2-ultralow expression, trastuzumab deruxtecan reduced the risk of disease progression or death by 22% compared with chemotherapy (HR, 0.78 [95% CI, 0.50-1.21); median PFS was ...

Since that time, HER2 has become one of the most drugged targets in oncology, with approvals of the antibody Perjeta/pertuzumab (Roche), the antibody-drug-conjugate Kadcyla/ado-trastuzumab ...

Topline results were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki in combination with pertuzumab as a first-line treatment for patients with human epidermal growth ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Treatment with Perjeta (pertuzumab), Herceptin (trastuzumab) and chemotherapy (Perjeta-based regimen) for one year as post-surgery treatment showed a statistically significant overall survival (OS) ...

Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naïve HER2-positive (HER2+) breast cancer ...

Circulating tumor DNA profiling can provide novel insights into gene alterations that underlie trastuzumab resistance in HER2+ metastatic gastric cancer.

Patients with metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer saw improvements in progression-free survival (PFS, the time a patient lives following treatment without a ...